COVID-19 vaccine effectiveness
(Randomized evidence)
Methods
Results of booster studies are available in the tables below and are updated on a monthly basis.
As of December 14, 2022, the COVID-NMA revised its protocol and discontinued the inclusion of prime vaccination trials in its analysis. The analysis presented on this page for prime vaccines compared to placebo or other vaccines includes trials that were identified and included up to December 14, 2022. A list of studies that were eligible up to this date but not extracted is provided in detail here .
On December 7, 2022, we published results of the systematic review "Efficacy and safety of COVID‐19 vaccines" which included 41 preprints and published trials of 12 different COVID-19 used as prime vaccination and that were published before 5 November 2021.meta-COVID
Perform your own analysis using COVID-NMA data for prime vaccination (last search date 14/12/2022), create and download your forest plots by clicking below:
Vaccine types
COVID-19 BOOSTER DOSE VACCINATION: updated daily
Vaccine efficacy, immunogenicity and safety of booster vs no booster (tables)
Vaccine efficacy, immunogenicity and safety of booster VS booster (tables)
COVID-19 PRIME VACCINATION: Last search date December 14, 2022.
Vaccine efficacy and safety for vaccine vs placebo / no vaccine (forest plots)
Vaccine efficacy and safety for vaccine vs vaccine (forest plots)
Vaccine efficacy, immunogenicity and safety of heterologous vs homologous vaccination (tables)
Vaccine efficacy and safety against variants of concern (forest plots)
Search studies
| Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
|
NCT04651790 Sinovac Research and Development Co., Ltd Abarca K, medRxiv, 2022 Full text Commentary Commentary Commentary |
Inactivated virus |
CoronaVac |
Coronavac D0/28 |
RCTPhase 3 | Healthy adults including health care workers with no history of confirmed symptomatic SARS CoV-2 infection at eight centres in Chile | N= 2302 |
Some concerns Details |
|
|
NCT04510207, ChiCTR2000034780 Sinopharm-Wuhan Al Kaabi N, JAMA, 2021 Full text Commentary Commentary |
Inactivated virus |
WIBP-CorV |
Adjuvant |
RCTPhase 3 | Healthy adults free of known COVID-19 or HIV infection at 3 centres in United Arab Emirates and Bahrain | N= 40411 |
Some concerns Details |
|
|
NCT04510207, ChiCTR2000034780 Sinopharm-Beijing Al Kaabi N, JAMA, 2021 Full text Commentary Commentary |
Inactivated virus |
BBIBP-CorV |
Adjuvant |
RCTPhase 3 | Healthy adults free of known COVID-19 or HIV infection at 3 centres in United Arab Emirates and Bahrain | N= 40411 |
Some concerns Details |
|
|
NCT05293548 National Vaccine and Serum Institute, China, Beijing Zhong Sheng Heng Pharmaceutical Technology, Lanzhou Institute of Biological Products; Sinopharm-Beijing Al Kaabi N, Signal Transduct Ther, 2023 Full text Commentary Commentary |
Protein subunit |
BBIBP-CorV/Boost NVSI-06-09 |
BBIBP-CorV/Boost BBIBP-CorV |
RCTPhase 2 | Healthy adults previously vaccinated with two or three doses of BBIBP-CorV at least 6 months prior to enrollment at a single center in United Arab Emirates | N= 516 |
Some concerns Details |
|
|
NCT04651790 Sinovac Research and Development Co., Ltd Bueno S, Clin Infect Dis, 2021 Full text Commentary Commentary |
Inactivated virus |
CoronaVac 3 mcg D0/14 |
Adjuvant D0/14 |
RCTPhase 3 | Adult healthcare workers with no history of confirmed symptomatic SARS-CoV-2 infection who were in contact with possible or confirmed cases of COVID-19 in 8 sites in Chile. | N= 434 |
Some concerns Details |
|
|
ChiCTR2100051998 Sinovac Research and Development Co. Ltd.; Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences Cao Y, Cell Res, 2021 Full text Commentary |
Inactivated virus |
CoronaVac/Boost ZF2001 |
CoronaVac/Boost CoronaVac |
RCTPhase 2 | Healthcare professionals with no previous confirmed COVID-19 at a single center in China who had received two doses of CoronaVac in a 28-day interval 4–8 months earlier | N= 164 |
Some concerns Details |
|
|
NCT04412538 Institute of Medical Biology (IMB), Chinese Academy of Medical Sciences (CAMS). Che Y, Clin Infect Dis, 2020 Full text Commentary |
Inactivated virus |
KMS-1 SARS-CoV-2 inactivated virus vaccine - medium dose (100 EU) x 2 doses on day 0/14 KMS-1 SARS-CoV-2 inactivated virus vaccine - high dose (150 EU) x 2 doses on day 0/14 KMS-1 SARS-CoV-2 inactivated virus vaccine - medium dose (100 EU) x 2 doses on day 0/14 KMS-1 SARS-CoV-2 inactivated virus vaccine - high dose (150 EU) x 2 doses on day 0/14 |
aluminum hydroxide adjuvant in saline buffer |
RCTPhase 2 | Healthy SARS-CoV-2 serology/DNA negative adults in two centres in China | N= 750 |
Some concerns Details |
|
|
RBR–9nn3scw AstraZeneca+University of Oxford/Sinovac/Janssen Pharmaceutical Companies/Pfizer/BioNTech+Fosun Pharma Costa Clemens SA, Lancet, 2022 Full text Commentary Commentary |
Non replicating viral vector |
CoronaVac/Boost BNT162b2 CoronaVac/Boost ChAdOx1 CoronaVac/Boost AD26.COV2-S |
CoronaVac/Boost CoronaVac |
RCTPhase 4 | Healthy adults with no history of confirmed covid-19 who had previously received 2 doses of CoronaVac at two centers in Brazil | N= 1240 |
Some concerns Details |
|
|
NCT04471519 Bharat Biotech Ella R, Lancet Infect Dis, 2021 a Updated Full text Commentary |
Inactivated virus |
2 dose 3mcg BBV152 nCoV-19 vaccine + Algel-IMDG adjuvant, Days 0/14, 0.5mL 2 dose 6mcg BBV152 nCoV-19 vaccine + Algel-IMDG adjuvant, Days 0/14, 0.5mL 2 dose 6mcg BBV152 nCoV-19 vaccine + Algel adjuvant, Days 0/14, 0.5mL |
Adjuvant (Algel) |
RCTPhase 1 | Healthy SARS-CoV-2 serology/PCR negative adults in 11 centres in India | N= 375 |
Some concerns Details |
|
|
NCT04471519 Bharat Biotech Ella R, Lancet Infect Dis, 2021 b Full text Commentary ; Commentary |
Inactivated virus |
BBV152 6mcg + Algel-IMDG D0/28 |
BBV152 6mcg + Algel-IMDG D0/28 |
RCTPhase 2 | Healthy adults (<65 yo) and children (≥12 yo)volunteers, SARS-CoV-2 infection-free in 9 centres in India | N= 380 |
Some concerns Details |
|
|
NCT04641481 Bharat Biotech Ella R, Lancet, 2021 b Full text Commentary |
Inactivated virus |
BBV152 |
Adjuvant |
RCTPhase 3 | Adults with no history of SARS-CoV-2 infection who were healthy or had stable chronic medical conditions at 25 centers in India | N= 25798 |
Some concerns Details |
|
|
NCT04508075 ; INA-WXFM0YX Sinovac Research and Development Co., Ltd Fadlyana E, Vaccine, 2021 Full text Commentary |
Inactivated virus |
CoronaVac |
Placebo |
RCTPhase 3 | Healthy adults aged 18 - 59 years, seropositive and seronegative, at a single center in Indonesia | N= 1620 |
Some concerns Details |
|
|
INA-GO0HLGB AstraZeneca+University of Oxford;Pfizer/BioNTech + Fosun Pharma; Sinovac, Ltd Fadlyana E, Lancet Infect Dis, 2023 Full text Full text Commentary Commentary Commentary |
RNA based vaccine |
CoronaVac/Boost BNT162b2 CoronaVac/Boost BNT162b2 CoronaVac/Boost BNT162b2 (half dose) Coronavac/Boost ChAdOx1 (half dose) |
CoronaVac/Boost CoronaVac CoronaVac/Boost BNT162b2 CoronaVac/Boost CoronaVac CoronaVac/Boost CoronaVac |
RCT* | Healthy adults without a history of laboratory confirmed COVID-19 within one month prior recruitment in 5 centres in Indonesia | N= 960 |
Some concerns Details |
|
|
ChiCTR2100041705, ChiCTR2100041706 Sinopharm-Beijing Feng Y, Infect. Dis. Poverty, 2021 Full text Commentary |
Inactivated virus |
BBIBP-CorV 0-14D BBIBP-CorV 0-21D |
BBIBP-CorV 0-28D |
RCT4 | Healthy adults from high-risk occupational population at a single center in China | N= 809 |
Some concerns Details |
|
|
ChiCTR2000031809 Sinopharm-Wuhan Guo W, EClinicalMedicine, 2021 Full text Commentary |
Inactivated virus |
WIBP-CorV 5 mcg D0/21 |
Adjuvant |
RCTPhase 1-2 | Healthy adults with no history of COVID-19 at 5 centers in China. | N= 1120 |
Some concerns Details |
|
|
NCT04551547 Sinovac Research and Development Co., Ltd Han B, Lancet Infect Dis, 2021 Full text (21)00319-4/fulltext; Full text Commentary |
Inactivated virus |
CoronaVac 1.5 mcg D0/28 CoronaVac 3 mcg D0/28 |
Adjuvant |
RCTPhase 1/2 | Healthy children and adolescents aged 3-17 years with no history of SARS-CoV-2 infection in a single centre in China. | N= 552 |
Some concerns Details |
|
|
NCT05046548 Chumakov FSC R&D IBP RAS Ishmukhametov AA, medRxiv, 2022 Full text Commentary Commentary |
Inactivated virus |
CoviVac D0/D14 |
Adjuvant |
RCTPhase 1-2 | Adults aged 18-60 without immunosuppression, seronegative and seropositive, at 3 centers in the Russian Federation | N= 400 |
Some concerns Details |
|
|
NCT04952727 CanSino Biological Inc./Beijing Institute of Biotechnology ; Sinovac Research and Development Co., Ltd Jin P, medRxiv, 2022 a Full text Commentary Commentary |
Non replicating viral vector |
CoronaVac/Boost Ad5-vectored 5×10^10 vp |
CoronaVac/Boost CoronaVac |
RCTPhase 4 | Adults aged ≥60 years without severe or unstable comorbidities or confirmed history of COVID-19 or SARS-CoV-2 infection at a single center in China. | N= 199 |
Some concerns Details |
|
|
NCT04952727 CanSino Biological Inc./Beijing Institute of Biotechnology ; Sinovac Research and Development Co., Ltd Jin P, medRxiv, 2022 b Full text Commentary Commentary |
Heterologous vaccination scheme |
CoronaVac/Ad5-nCoV |
CoronaVac |
RCTPhase 4 | Adults aged ≥60 years without severe or unstable comorbidities or confirmed history of COVID-19 or SARS-CoV-2 infection at a single center in China. | N= 100 |
Some concerns Details |
|
|
NCT04691908 Research Institute for Biological Safety Problems, Rep of Kazakhstan Khairullin B, EClinicalMedicine, 2022 Full text Commentary Commentary |
Inactivated virus |
QazCovid-in 5mcg D0/D21 |
Adjuvant |
RCTPhase 3 | Healthy adults or those with chronic diseases, with no known or suspected history of COVID-19 at 3 centers in Kazakhstan | N= 3000 |
Some concerns Details |
|
|
NCT04864561 Valneva Lazarus R, Lancet Infect Dis, 2022 Full text Commentary |
Inactivated virus |
VLA2001 |
ChAdOx1 |
RCTPhase 3 | Medically stable adults, 30 years and older, at 26 centers in the UK. | N= 2975 |
Some concerns Details |
|
|
NCT04671017; ISRCTN 82411169 Valneva Austria GmbH Lazarus R, J Infect, 2022 Full text Full text Full text Commentary |
Inactivated virus |
VL A2001 3AU VL A2001 3AU |
VL A2001 35AU VL A2001 7AU |
RCTPhase 1-2 | Healthy adult volunteers aged 18-55 at 4 centers in the UK | N= 153 |
Some concerns Details |
|
|
NCT04892459 Sinovac Research and Development Co Ltd+CanSino Biological Inc / Beijing Institute of Biotechnology Li J, Nat. Med., 2022 Full text Commentary |
Non replicating viral vector |
1 dose CoronaVac / 1 dose Ad5-vectored |
2 doses CoronaVac |
RCTPhase 4 | Healthy adults with no previous clinical or virologic COVID-19 diagnosis or SARS-CoV-2 infection at one centre in China | N= 100 |
Some concerns Details |
|
|
NCT04892459 Sinovac Research and Development Co Ltd + CanSino Biological Inc /Beijing Institute of Biotechnology Li J, Nat. Med., 2022 Full text Commentary |
Non replicating viral vector |
CoronaVac/boost Ad5-vectored 5×10^10 vp |
CoronaVac/boost |
RCTPhase 4 | Healthy adults with no previous clinical or virologic COVID-19 diagnosis or SARS-CoV-2 infection at one centre in China | N= 200 |
Some concerns Details |
|
|
NCT04383574 Sinovac Research and Development Co., Ltd Li M, medRxiv, 2021 Full text Commentary Commentary |
Inactivated virus |
CoronaVac 3 mcg |
Placebo |
RCTPhase 2 | Healthy adults aged ≥60 years with no known history of COVID-19 or recent exposure in a single center in China. | N= 350 |
Some concerns Details |
|
|
ChiCTR2000039462 Shenzhen Kangtai Biological Products Co. Ltd.; Beijing Minhai Biotechnology Co. Ltd. Liu J, J Infect Dis, 2021 Full text Commentary |
Inactivated virus |
KCONVAC 10mcg D0/28/56 KCONVAC 5mcg D0/28/56 |
Placebo |
RCTPhase 2 | Healthy adults aged 18-59 and ≥60 with no history of COVID-19 and seronegative at a single center in China | N= 500 |
Low Details |
|
|
NCT04962906; NCT05027672 Gamaleya Research Institute, AstraZeneca+University of Oxford;Moderna;Sinopharm Macchia A, Lancet Reg Health Am, 2022 Full text Commentary |
Non replicating viral vector |
Gam-COVID-Vac rAd26-S |
Gam-COVID-Vac rAd26-S/BBIBP-CorV |
RCTPhase 2 | Adults who had received the first dose (rAd26) of the Sputnik V vaccine at least 30 days earlier and no history of SARS-CoV-2 at a single centre in Argentina | N= 540 |
Some concerns Details |
|
|
NCT04611243 Sinovac/Pfizer/BioNTech+Fosun Pharma Mok C K P, Am. J. Respir. Crit., 2022 Full text Commentary |
RNA based vaccine |
CoronaVac/Boost CoronaVac |
CoronaVac/Boost BNT162b2 |
RCT* | Adults that had received two doses of CoronaVac but had low immune response against SARS-CoV-2 at two centres in Hong Kong, China | N= 80 |
Some concerns Details |
|
|
NCT04456595 Sinovac Research and Development Co., Ltd Palacios R, SSRN, 2021 PROFISCOV Full text Commentary |
Inactivated virus |
CoronaVac 3mcg D0/14 |
Adjuvant D0/14 |
RCTPhase 3 | Healthcare professionals with or without previous COVID-19 infection caring for COVID-19 patients at 16 centers in Brazil. | N= 12408 |
Some concerns Details |
|
|
NCT04352608 Sinovac Research and Development Co., Ltd Pan H , medRxiv, 2021 Full text Commentary Commentary |
Inactivated virus |
CoronaVac 3mcg 0/28/56 CoronaVac 6mcg 0/28/56 |
Placebo |
RCTPhase 2 | Healthy adults 18-59 years that were SARS-CoV-2 infection and antibody free at a single centre in China | N= 150 |
Some concerns Details |
|
|
NCT04352608 Sinovac Research and Development Co., Ltd Pan H, medRxiv, 2021 Full text Commentary Commentary |
Inactivated virus |
CoronaVac 3mcg D0/14/42 CoronaVac 6mcg D0/14/42 |
Placebo |
RCTPhase 2 | Healthy adults 18-59 years that were SARS-CoV-2 infection and antibody free at a single centre in China | N= 150 |
Some concerns Details |
|
|
NCT04352608 Sinovac Research and Development Co Ltd Pan H , medRxiv, 2021 b Full text Commentary Commentary |
Inactivated virus |
CoronaVac 3mcg 0/28/208 CoronaVac 6mcg 0/28/208 |
Placebo |
RCTPhase 2 | Healthy adults 18-59 years that were SARS-CoV-2 infection and antibody free at a single centre in China | N= 150 |
Some concerns Details |
|
|
NCT04352608 Sinovac Research and Development Co Ltd Pan H , medRxiv, 2021 Full text Commentary Commentary |
Inactivated virus |
CoronaVac 3mcg 0/14/194 CoronaVac 6mcg 0/14/194 |
Placebo |
RCTPhase 2 | Healthy adults 18-59 years that were SARS-CoV-2 infection and antibody free at a single centre in China | N= 150 |
Some concerns Details |
|
|
NCT04756323, ChiCTR2000039462 Shenzhen Kangtai Biological Products and Beijing Minhai Biotechnology Pan HX, Chin Med J, 2022 b Full text Commentary |
Inactivated virus |
5mcg KCONVAC D0/14 5mcg KCONVAC D0/14 5mcg KCONVAC D0/28 5mcg KCONVAC D0/28 5mcg KCONVAC D0/14 10mcg KCONVAC D0/14 |
10mcg KCONVAC D0/14 5mcg KCONVAC D0/14 10mcg KCONVAC D0/28 Adjuvant Adjuvant Adjuvant |
RCTPhase 2 | Healthy adult volunteers with no history of COVID-19 and HIV- and SARS-CoV-2 infection-free in a single centre in China. | N= 500 |
Low Details |
|
|
NCT04758273, ChiCTR2000038804 Shenzhen Kangtai Biological Products and Beijing Minhai Biotechnology Pan HX, Chin Med J, 2022 a Full text Commentary |
Inactivated virus |
KCONVAC 5mcg D0/14 |
KCONVAC 10mcg D0/14 |
RCTPhase 1 | Healthy adult volunteers, 18 to 59 years of age, with no history of COVID-19 and HIV- and SARS-CoV-2 infection-free in a single centre in China. | N= 60 |
Low Details |
|
|
NCT04764422 The Government Pharmaceutical Organization (GPO); PATH; Dynavax Pitisuttithum P, medRxiv, 2021 Full text Commentary Commentary |
Inactivated virus |
NDV-HXP-S 1mcg NDV-HXP-S 1mcg + CpG1018 NDV-HXP-S 3mcg NDV-HXP-S 3mcg + CpG1018 NDV-HXP-S 10mcg NDV-HXP-S 1mcg |
Placebo |
RCTPhase 1 | Healthy adults without immunosuppression negative for SARS-CoV-2 antibodies at a single center in Thailand | N= 210 |
Some concerns Details |
|
|
NCT04412538 The Institute of Medical Biology (IMB), Chinese Academy of Medical Sciences (CAM Pu J, Vaccine, 2021 Full text Commentary |
Inactivated virus |
2 IM doses of 100 EU SARS-CoV-2 inactivated vaccine (medium dose), on day 0,14 2 IM doses of 100 EU SARS-CoV-2 inactivated vaccine (medium dose), on day 0, 28 |
2 IM doses of aluminum hydroxide adjuvant in saline buffer, on day 0, 14 |
RCTPhase 1 | Healthy adults aged 18 to 59 years, SARS-CoV-2 nucleic acid or antibodies negative in a single centre in China | N= 192 |
Some concerns Details |
|
|
CTRI/2021/08/035648 AstraZeneca + University of Oxford; Bharat Biotech Rose W, Lancet Reg Health Southeast Asia, 2023 Full text Full text Commentary Commentary |
Inactivated virus |
ChadOx1/Boost BBV152 BBV152/Boost ChadOx1 |
ChadOx1/Boost ChadOx1 BBV152/Boost BBV152 |
RCTPhase 4 | Adults that were SARS-CoV-2 infection-free in a single centre in India | N= 405 |
Low Details |
|
|
NCT04582344 Sinovac Research and Development Co., Ltd Tanriover M, Lancet , 2021 Full text Commentary Commentary |
Inactivated virus |
CoronaVac |
Adjuvant |
RCTPhase 3 | Healthy healthcare workers and adults aged 18–59 years with no history of COVID-19 from 24 centres in Turkey | N= 10218 |
Some concerns Details |
|
|
NCT04942405 Erciyes University, Health Institutes of Turkey (TUSEB);Sinovac Research and Development Tanriover M, Vaccines, 2022 Full text Commentary |
Inactivated virus |
TURKOVAC |
CoronaVac |
RCTPhase 3 | Adults including healthy and with stable co-morbidities with no history of COVID-19 in 8 centres in Türkiye. | N= 1290 |
Some concerns Details |
|
|
NCT04471519; CTRI/2021/04/032942 Bharat Biotech Vadrevu KM, Sci Rep, 2022 Full text Full text Commentary Commentary |
Inactivated virus |
BBV152/Boost BBV152 |
BBV152/Boost placebo |
RCTPhase 2 | Adolescents and adults aged 12-64 years with no history of confirmed COVID-19, who had received a 2-dose schedule of the same vaccine 6 months previously at 9 centers in India. | N= 184 |
Some concerns Details |
|
|
NCT04551547 Sinovac Wang L, Nat Commun, 2022 New Full text Commentary Commentary |
Inactivated virus |
Coronavac 1.5mcg/boost Coronavac 1.5 mcg |
Coronavac 3 mcg/boost Coronavac 3 mcg |
RCTPhase 2 | Children and adolescents aged 3-17 years without previous history of SARS-CoV-2 infection at a single center in China. | N= 346 |
Some concerns Details |
|
|
NCT04383574 Sinovac Research and Development Co., Ltd Wu Z, Lancet Infect Dis, 2021 Full text Commentary ; Commentary |
Inactivated virus |
CoronaVac, 1.5mcg virus material inactivated SARS-CoV-2 whole virion vaccine, day 0/28 CoronaVac, 3mcg virus material inactivated SARS-CoV-2 whole virion vaccine, day 0/28 CoronaVac, 6mcg virus material inactivated SARS-CoV-2 whole virion vaccine, day 0/28 |
Adjuvant (Aluminum hydroxide) |
RCTPhase 1/2 | Healthy adults aged 60 years and older with no history of SARS-CoV-2 infection in a single centre in China | N= 422 |
Some concerns Details |
|
|
ChiCTR2000032459 Sinopharm-Beijing Xia S , Lancet, 2021 Full text Commentary |
Inactivated virus |
BBIBP-CorV |
Adjuvant |
RCTPhase 1-2 | Healthy children and adolescents aged 3 to 17 years free from SARS-CoV-2 infection and antibodies at a single centre in China | N= 1008 |
Low Details |
|
|
ChiCTR2000031809 Sinopharm-Wuhan Xia S, JAMA, 2020 Full text Commentary |
Inactivated virus |
WIBP-CorV 5mcg-D0/28/56 |
Placebo |
RCTPhase 1 | Healthy adults, aged 18 to 59 years, without history ofSARS-CoV(via on-site inquiry) or SARS-CoV-2 infection (via serologicaland nucleic acid test | N= NR |
Low Details |
|
|
ChiCTR2000032459 Sinopharm-Beijing Xia S, Lancet Infect Dis, 2020 Full text Commentary |
Inactivated virus |
BBIBP-CorV 8mcg Day 0 |
Adjuvant |
RCTPhase 2 | Healthy SARS-CoV-2 serology negative adults 18-59 years old in a single centre in China | N= 448 |
Some concerns Details |
|
|
ChiCTR2000031809 Sinopharm-Wuhan Xia S, JAMA, 2020 Full text Commentary |
Inactivated virus |
WIBP-CorV 5mcg-D0/14 |
Placebo |
RCTPhase 2 | Healthy adults, aged 18 to 59 years, without history ofSARS-CoV(via on-site inquiry) or SARS-CoV-2 infection (via serologicaland nucleic acid test | N= NR |
Some concerns Details |
|
|
ChiCTR2000032459 Sinopharm-Beijing Xia S, Lancet Infect Dis, 2020 Full text Commentary |
Inactivated virus |
BBIBP 4mcg |
Placebo |
RCTPhase 1 | Healthy adults SARS-CoV-2 serology negative adults in a single centre in China | N= 192 |
Low Details |
|
|
NCT04530357 Research Institute for Biological Safety Problems, Rep of Kazakhstan Zakarya K , EClinicalMedicine, 2021 Full text Commentary |
Inactivated virus |
QazCovid-in |
QazCovid-in D1 |
RCTPhase 2 | Healthy adults with no history of COVID-19 that tested negative for SARS-CoV-2 and HIV virus at a single centre in Kazakhstan. | N= 200 |
Some concerns Details |
|
|
NCT04530357 Research Institute for Biological Safety Problems, Rep of Kazakhstan Zakarya K, EClinicalMedicine, 2021 a Full text Commentary |
Inactivated virus |
QazCovid-in |
Placebo |
RCTPhase 1 | Healthy adults with no history of COVID-19 that tested negative for SARS-CoV-2 and HIV virus at a single centre in Kazakhstan. | N= 44 |
Some concerns Details |
|
|
NCT04352608, NCT04383574 Sinovac Research and Development Co., Ltd Zeng G, Lancet Infect Dis, 2021 Full text Full text Commentary |
Inactivated virus |
Coronavac/Boost CoronaVac at 2 months Coronavac/Boost CoronaVac at 8 months |
Coronavac/Boost placebo at 2 months Coronavac/Boost placebo at 8 months |
RCTPhase 2 | Healthy adults and older adults without suspected or laboratory-confirmed SARS-CoV-2 infections in 2 centres in China | N= 510 |
Some concerns Details |
|
|
ChiCTR2200057758 Walvax Biotech Co., Ltd ; Walvax Biotechnology + Shanghai RNACure Biopharma ; Shanghai Zerun Biotechnology + Walvax Biotechnology + CEPI ; Sinovac Research an Zhang Y, Nature, 2023 Full text Full text Commentary |
Non replicating viral vector |
CoronaVac/Boost ChAdTS-S CoronaVac/Boost RQ3013 CoronaVac/Boost ZR202-CoV CoronaVac/Boost CoronaVac |
CoronaVac/Boost placebo |
RCTPhase 2 | Adults aged 18-59, healthy or with stable pre-existing disease and with no history of SARS-CoV-2 infection, at a single center in China. | N= 250 |
Some concerns Details |
|
|
NCT04352608 Sinovac Research and Development Co., Ltd Zhang Y, Lancet Infect Dis, 2020 Full text Commentary ; Commentary |
Inactivated virus |
CoronaVac 6 mcg D0/28 CoronaVac 3 mcg D0/28 CoronaVac 6 mcg D0/14 CoronaVac 3 mcg D0/14 |
Adjuvant |
RCTPhase 1 | Healthy SARS-CoV-2 serology/DNA negative adults in a single centre in China | N= 144 |
Some concerns Details |
|
|
NCT04352608 Sinovac Research and Development Co., Ltd Zhang Y, Lancet Infect Dis, 2020 Full text Commentary ; Commentary |
Inactivated virus |
CoronaVac 3 mcg D0/14 CoronaVac 6 mcg D0/14 CoronaVac 3 mcg D0/28 CoronaVac 6 mcg D0/28 |
Adjuvant |
RCTPhase 2 | Healthy SARS-CoV-2 serology/DNA negative adults in a single centre in China | N= 600 |
Some concerns Details |
|